Article
Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 Jan 2014
Dijkstra Maaike G, van Niekerk Dirk, Rijkaart Dorien C, van Kemenade Folkert J, Heideman Daniëlle A M, Snijders Peter J F, Meijer Chris J L M, Berkhof Johannes
Abstract excerpt
BACKGROUND: High-risk human papillomavirus (hrHPV) testing has higher sensitivity but lower specificity than cytology for cervical (pre)-cancerous lesions. Therefore, triage of hrHPV-positive women is needed in cervical cancer screening. METHODS: A cohort of 1,100 hrHPV-positive women, from a population-based screening trial (POBASCAM: n = 44,938; 29-61 years), was used to evaluate 10 triage strategies, involving...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.